13 results match your criteria: "Sichuan Clinical Research Centre for Kidney Diseases[Affiliation]"
The immune regulatory role of lymphangiogenesis in kidney disease.
J Transl Med
November 2024
Department of Nephrology and Institute of Nephrology, Sichuan Provincial People's Hospital, Sichuan Clinical Research Centre for Kidney Diseases, Chengdu, China.
Article Synopsis
- - The renal lymphatic system plays a vital role in maintaining kidney health and managing the immune response within the kidney, especially during pathological conditions.
- - Kidney lymphangiogenesis, the formation of new lymphatic vessels, impacts immune response by affecting lymphatic flow and immune cell movement, but its effects can vary across different kidney diseases.
- - Ongoing research aims to clarify the complex and contradictory roles of lymphangiogenesis in renal disorders, potentially leading to new therapeutic strategies targeting lymphatics for kidney disease treatment.
Correction: Occurrence and role of Tph cells in various renal diseases.
Mol Med
November 2024
Department of Nephrology, Institute of Nephrology, Sichuan Provincial People's Hospital, Sichuan Clinical Research Centre for Kidney Diseases, Chengdu, China.
Histone deacetylase 9 promotes osteogenic trans-differentiation of vascular smooth muscle cells via ferroptosis in chronic kidney disease vascular calcification.
Ren Fail
December 2024
Department of Nephrology and Institute of Nephrology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Sichuan Clinical Research Centre for Kidney Diseases, Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Chengdu, China.
Vascular calcification, a common complication of chronic kidney disease (CKD), remains an unmet therapeutic challenge. The trans-differentiation of vascular smooth muscle cells (VSMCs) into osteoblast-like cells is crucial in the pathogenesis of vascular calcification in CKD. Despite ferroptosis promotes vascular calcification in CKD, the upstream or downstream regulatory mechanisms involved remains unclear.
View Article and Find Full Text PDFComparison of efficacy and safety of different anticoagulation regimens in plasma exchange: A systematic review and meta-analysis.
PLoS One
October 2024
Department of Nephrology and Institute of Nephrology, Sichuan Clinical Research Centre for Kidney Diseases, School of Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Article Synopsis
- - The study investigates the effectiveness and safety of various anticoagulation methods used during plasma exchange (PE), noting that current methods can lead to clotting issues that waste nursing resources.
- - A systematic review included 7 studies involving over 1,600 patients, finding that unfractionated heparin (UFH) was better than saline for preventing clotting but showed similar results to low-molecular-weight heparin (LMWH) and regional citrate anticoagulation (RCA).
- - The findings suggest that while current anticoagulation methods are generally effective, there's a risk of longer post-treatment aPTT (a clotting test) and lower platelet counts with UFH; however, more research is needed for
Urinary Soluble CD163: A Novel Biomarker Suggests Who Should Receive Glucocorticoids in IgA Nephropathy.
Kidney Int Rep
October 2024
Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Occurrence and role of Tph cells in various renal diseases.
Mol Med
October 2024
Department of Nephrology and Institute of Nephrology, Sichuan Provincial People's Hospital, Sichuan Clinical Research Centre for Kidney Diseases, Chengdu, China.
Article Synopsis
- A new type of T cell, called peripheral helper T (Tph) cells, has been linked to autoimmune diseases and has a unique role in regulating kidney-related conditions.
- Tph cells secrete important immune molecules like interleukin-21 (IL-21) and interferon (IFN) and can gather in large groups within inflamed tissues.
- Compared to T follicular helper (Tfh) cells, Tph cells express higher levels of specific proteins (like PD-1 and MHC-II) and have distinct characteristics that enhance B cell responses in inflamed areas of the body.
Hypoxia-inducible factor-prolyl hydroxylase inhibitors for treatment of anemia in chronic kidney disease: a systematic review and network meta-analysis.
Front Pharmacol
July 2024
Department of Nephrology and Institute of Nephrology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, School of Medicine, Sichuan Clinical Research Centre for Kidney Diseases, University of Electronic Science and Technology of China, Chengdu, China.
Article Synopsis
- - The study reviews the effectiveness and safety of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHIs) in treating anemia in chronic kidney disease (CKD) patients, focusing particularly on their safety profiles.
- - A comprehensive analysis of 47 studies, including 55 randomized controlled trials, found that all six commercially available HIF-PHIs can effectively increase hemoglobin levels compared to placebo, with no significant safety risks compared to traditional treatments like erythropoiesis stimulating agents (ESAs).
- - Despite the positive findings, the study highlights the need for more long-term research and continued monitoring to ensure ongoing safety and efficacy for HIF-PHIs in CKD
Metabolic disorders, including obesity, dyslipidemia, diabetes, nonalcoholic fatty liver disease, and metabolic syndrome, are characterized by insulin resistance, abnormalities in circulating cholesterol and lipid profiles, and hypertension. The most common pathophysiologies of metabolic disorders are glucose/lipid metabolism dysregulation, insulin resistance, inflammatory response, and oxidative stress. Although several agents have been approved for the treatment of metabolic disorders, there is still a strong demand for more efficacious drugs with less side effects.
View Article and Find Full Text PDFProjecting the clinical burden of chronic kidney disease at the patient level (): a microsimulation modelling study.
EClinicalMedicine
June 2024
HealthLumen Limited, London EC3N 2PJ, UK.
Background: Chronic kidney disease (CKD) is a global concern that presents significant challenges for disease management. Several factors drive CKD prevalence, including primary risk factors, such as type 2 diabetes and hypertension, and an ageing population. is an international initiative that aims to raise awareness of the substantial burden incurred by CKD.
View Article and Find Full Text PDFAdverse renal outcomes following targeted therapies in renal cell carcinoma: a systematic review and meta-analysis.
Front Pharmacol
June 2024
Robotic Minimally Invasive Surgery Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
To clarify the prevalence of adverse renal outcomes following targeted therapies in renal cell carcinoma (RCC). A systematic search was performed in MEDLINE, EMBASE, and Cochrane Central Library. Studies that had reported adverse renal outcomes following targeted therapies in RCC were eligible.
View Article and Find Full Text PDFM133S mutation possibly involve in the ER stress and mitophagy pathway in maintenance hemodialysis patients with occult hepatitis B infection.
Sci Rep
June 2024
Department of Nephrology and Institute of Nephrology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Sichuan Clinical Research Centre for Kidney Diseases, Chengdu, 610072, Sichuan, China.
Article Synopsis
- Occult hepatitis B virus infection (OBI) involves the presence of HBV DNA without detectable HBsAg, posing risks for serious liver conditions like cirrhosis and cancer, although its mechanisms remain unclear.
- The study focused on the M133S mutation in the HBV S gene, found in hemodialysis patients, examining how amino acid changes affect S protein production and secretion via various scientific methods.
- Results indicated that the M133S mutation leads to a misfolded S protein that aggregates in the endoplasmic reticulum, impacting gene expression related to protein processing and associated with increased chaperone proteins and co-localization markers.
The predictive value of systemic immune-inflammation index for vascular access survival in chronic hemodialysis patients.
Front Immunol
June 2024
Department of Nephrology and Institute of Nephrology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Sichuan Clinical Research Centre for Kidney Diseases, Chengdu, China.
Article Synopsis
- The study aimed to explore how systemic immune-inflammation indices can predict vascular access failure in patients undergoing hemodialysis (HD).
- It analyzed data from 2,690 patients who received HD vascular access surgeries, finding that certain indices, particularly the SII, were strongly associated with access failure.
- A prediction model using the SII was created to forecast HD access survival rates, showing promising results that could be enhanced with larger, multi-center studies.
Piperacillin/tazobactam and risk of acute kidney injury in adults hospitalized with infection without vancomycin: a multi-centre real-world data analysis.
Int J Antimicrob Agents
January 2023
National Clinical Research Centre for Kidney Disease, State Key Laboratory of Organ Failure Research, Guangdong Provincial Clinical Research Centre for Kidney Disease, Guangdong Provincial Institute of Nephrology, Guangdong Provincial Key Laboratory of Renal Failure Research, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou City, Guangdong Province, China. Electronic address:
Background: There is uncertainty about whether piperacillin/tazobactam (PT) increases the risk of acute kidney injury (AKI) in patients without concomitant use of vancomycin. This study compared the risk of hospital-acquired AKI (HA-AKI) among adults treated with PT or antipseudomonal β-lactams (meropenem, ceftazidime) without concomitant use of vancomycin.
Methods: This real-world study analysed the data from China Renal Data System and assessed the risk of HA-AKI in adults hospitalized with infection after exposure to PT, meropenem or ceftazidime in the absence of concomitant vancomycin.